|
|
|
|
|
Vancouver-based Sierra Oncology Launches the MOMENTUM Phase 3 Clinical Trial
|
|
Vancouver, BC, November 22, 2019--Sierra Oncology, Inc. (Nasdaq: SRRA), a late-stage drug development company focused on the development and commercialization of momelotinib, a JAK1, JAK2 & ACVR1 inhibitor with a potentially differentiated therapeutic profile for the treatment of myelofibrosis, announced that it has launched the MOMENTUM clinical trial for patients with myelofibrosis.
|
|
|
|
|
|
|
|
Sierra Oncology and Gilead Sciences Agree on Amendments to Asset Purchase Agreement for Momelotinib
|
|
Vancouver, BC, November 15, 2019--Sierra Oncology, Inc. (Nasdaq: SRRA), a late-stage drug development company focused on the development and commercialization of momelotinib, a JAK1, JAK2 & ACVR1 inhibitor with a potentially differentiated therapeutic profile for the treatment of myelofibrosis, announced that it has agreed to amend its Asset Purchase Agreement with Gilead Sciences, Inc. for momelotinib (upon Sierra closing a qualified financing).
|
|
|
|
|
|
|
|
|
|
Sierra Oncology Reports Third Quarter 2019 Results
|
|
Vancouver, BC, November 7, 2019--Sierra Oncology, Inc. (SRRA), a late-stage drug development company focused on advancing targeted therapeutics for the treatment of patients with significant unmet needs in hematology and oncology, reported its financial and operational results for the third quarter ended September 30, 2019.
|
|
|
|
|
|
|
|
Vancouver-based Sierra Oncology Announces Momelotinib Granted FDA 'Fast Track' Designation
|
|
Vancouver, BC, June 11, 2019--Sierra Oncology, Inc. (SRRA), a late-stage drug development company focused on advancing targeted therapeutics for the treatment of patients with significant unmet needs in hematology and oncology, announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to momelotinib, a JAK1, JAK2 and ACVR1 inhibitor, for the treatment of patients with intermediate/high-risk myelofibrosis who have previously received a JAK inhibitor.
|
|
|
|
|
|
|
|
|
|
Sierra Oncology Reports Robust Transfusion Independence Rates in Transfusion Dependent Myelofibrosis Patients
|
|
Vancouver, BC, January 30, 2019--Sierra Oncology, Inc. (Nasdaq: SRRA), a clinical stage drug development company focused on advancing targeted therapeutics for the treatment of patients with significant unmet needs in hematology and oncology, reported clinical data for its lead drug candidate, momelotinib, a potent, selective and orally-bioavailable JAK1, JAK2 and ACVR1 inhibitor for the treatment of myelofibrosis.
|
|
|
|
|
|
|
|
Sierra Oncology Reports Third Quarter Results - Cash and Cash Equivalents Totaled $107.8 Million
|
|
Vancouver, BC, December 6, 2017--Sierra Oncology, Inc. (NASDAQ: SRRA), a clinical stage drug development company focused on advancing next generation DNA Damage Response (DDR) therapeutics for the treatment of patients with cancer, reported its financial and operational results for the third quarter ended September 30, 2017. Cash and cash equivalents totaled $107.8 million at the end of this quarter.
|
|
|
|
|
|
|
News
Events
Tech Careers
Directory
Tech Stocks
T-Net 100
Members
Feedback
About T-Net
Employers
Post Job Listings
Advertise
